

Marc L Berger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9251039/marc-l-berger-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57 papers	3,585 citations	27 h-index	59 g-index
59 ext. papers	3,985 ext. citations	4.6 avg, IF	4.68 L-index

#	Paper	IF	Citations
57	Toward Facilitated Self-Service in Health Care. <i>New England Journal of Medicine</i> , 2019 , 380, 1891-1893	59.2	5
56	Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. <i>Value in Health</i> , 2019 , 22, 13-20	3.3	45
55	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017 , 20, 1003-1008	3.3	113
54	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017 , 20, 1009-1022	3.3	47
53	Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. <i>Medical Care</i> , 2017 , 55, 244-251	3.1	8
52	Big Data: transforming drug development and health policy decision making. <i>Health Services and Outcomes Research Methodology</i> , 2016 , 16, 92-102	1.6	15
51	Opportunities and challenges in leveraging electronic health record data in oncology. <i>Future Oncology</i> , 2016 , 12, 1261-74	3.6	62
50	Optimizing the leveraging of real-world data to improve the development and use of medicines. <i>Value in Health</i> , 2015 , 18, 127-30	3.3	35
49	A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. <i>Value in Health</i> , 2014 , 17, 143-56	3.3	77
48	Big data, advanced analytics and the future of comparative effectiveness research. <i>Journal of Comparative Effectiveness Research</i> , 2014 , 3, 167-76	2.1	29
47	Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. <i>Value in Health</i> , 2012 , 15, 217-30	3.3	120
46	The role of private industry in pragmatic comparative effectiveness trials. <i>Journal of Comparative Effectiveness Research</i> , 2012 , 1, 147-56	2.1	10
45	Raising the bar of efficacy for drug approval requires an understanding of patient diversity. <i>Journal of Clinical Oncology</i> , 2010 , 28, e343-4; author reply e345	2.2	4
44	Comparative effectiveness research: the view from a pharmaceutical company. <i>Pharmacoeconomics</i> , 2010 , 28, 915-22	4.4	7
43	GRACE principles: recognizing high-quality observational studies of comparative effectiveness. <i>American Journal of Managed Care</i> , 2010 , 16, 467-71	2.1	90
42	Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I. <i>Value in Health</i> , 2009 , 12, 1044-52	3.3	236
41	Getting real performance out of pay-for-performance. <i>Milbank Quarterly</i> , 2008 , 86, 435-57	3.9	19

40	Valuing reductions in on-the-job illness: S presenteeism S from managerial and economic perspectives. <i>Health Economics (United Kingdom)</i> , 2008 , 17, 469-85	2.4	117
39	Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. <i>American Journal of Health-System Pharmacy</i> , 2007 , 64, 637-43	2.2	28
38	The decision to conduct a head-to-head comparative trial: a game-theoretic analysis. <i>Medical Decision Making</i> , 2007 , 27, 364-79	2.5	4
37	Measuring the effects of work loss on productivity with team production. <i>Health Economics (United Kingdom)</i> , 2006 , 15, 111-23	2.4	117
36	How to present the business case for healthcare quality to employers. <i>Applied Health Economics and Health Policy</i> , 2005 , 4, 209-18	3.4	25
35	Evidence synthesis and evidence-based decision making: related but distinct processes. <i>Medical Decision Making</i> , 2005 , 25, 487-9	2.5	14
34	Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. <i>Clinical Therapeutics</i> , 2005 , 27, 960-9	3.5	22
33	Osteoporosis and fracture risk in women of different ethnic groups. <i>Journal of Bone and Mineral Research</i> , 2005 , 20, 185-94	6.3	380
32	Cost-Effectiveness Analysis. <i>Medical Care</i> , 2005 , 43, II-49	3.1	12
31	Comparative effectiveness: asking the right questions, choosing the right method. <i>Health Affairs</i> , 2005 , 24, 128-32	0	36
30	Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. <i>American Journal of Managed Care</i> , 2005 , 11, 621-8	2.1	46
29	Bone Mineral Density Thresholds for Pharmacologic Intervention to Prevent Fractures. <i>Obstetrical and Gynecological Survey</i> , 2004 , 59, 769-771	2.4	2
28	A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. <i>Preventing Chronic Disease</i> , 2004 , 1, A05	3.7	15
27	Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. <i>Menopause</i> , 2003 , 10, 412-9	2.5	49
26	A general model of the impact of absenteeism on employers and employees. <i>Health Economics (United Kingdom)</i> , 2002 , 11, 221-31	2.4	102
25	Treatment of migraine with rizatriptan: when to take the medication. <i>Headache</i> , 2002 , 42, 16-20	4.2	39
24	Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 2222-30	6.3	246
23	Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1951-8	0.7	47

22	A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. <i>Journal of Rheumatology</i> , 2002 , 29, 804-12	4.1	150
21	Growth in use of lipid-lowering therapies: are we targeting the right patients?. <i>American Journal of Managed Care</i> , 2002 , 8, 862-7	2.1	10
20	Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. <i>American Journal of Managed Care</i> , 2002 , 8, 937-46	2.1	5
19	Disease Management: An Intermediate Step Toward Integrated and Coordinated Patient Care. <i>Disease Management: DM</i> , 2001 , 4, 173-178		1
18	Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 2815-22	27.4	825
17	The Value of Disease Management. <i>Disease Management and Health Outcomes</i> , 2000 , 8, 181-184		4
16	A Population-Based Approach to Asthma Disease Management. <i>Disease Management and Health Outcomes</i> , 2000 , 7, 179-186		12
15	Efficient patient identification strategies for women with osteoporosis. <i>Journal of Clinical Densitometry</i> , 1999 , 2, 223-30	3.5	14
14	Effectiveness of antihyperlipidemic drug management in clinical practice. <i>Clinical Therapeutics</i> , 1999 , 21, 1973-87	3.5	9
13	Quality-of-life questionnaire for patients taking antihypertensive medication. <i>Clinical Therapeutics</i> , 1999 , 21, 1771-87	3.5	10
12	The once and future application of cost-effectiveness analysis. <i>The Joint Commission Journal on Quality Improvement</i> , 1999 , 25, 455-61		9
11	A Comparison of the Tolerability and Efficacy of Lovastatin 20 mg and Fluvastatin 20 mg in the Treatment of Primary Hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996 , 1, 101-106	2.6	11
10	Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group. <i>American Journal of Cardiology</i> , 1996 , 77, 475-9	3	18
9	Novel oral medication delivery system for famotidine. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 362-7	2.9	6
8	Anoxic hepatocyte injury: role of reversible changes in elemental content and distribution. <i>Hepatology</i> , 1989 , 9, 219-28	11.2	27
7	Toxicity of methylating agents in isolated hepatocytes. <i>Biochemical Pharmacology</i> , 1988 , 37, 3183-8	6	30
6	Studies on calcium transport during carbon tetrachloride mediated hepatotoxicity in mice. <i>Biochemical Pharmacology</i> , 1988 , 37, 4584-6	6	4
5	Intervention in free radical mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol. <i>Biochemical Pharmacology</i> , 1988 , 37, 333-8	6	65

4	Rapid halogenated hydrocarbon toxicity in isolated hepatocytes is mediated by direct solvent effects. <i>Toxicology</i> , 1987 , 45, 319-30	4.4	15
3	Carbon tetrachloride-induced morphologic alterations in isolated rat hepatocytes. <i>Experimental and Molecular Pathology</i> , 1987 , 46, 245-57	4.4	21
2	CCl ₄ -induced toxicity in isolated hepatocytes: the importance of direct solvent injury. <i>Hepatology</i> , 1986 , 6, 36-45	11.2	97
1	Scurvy as an initial manifestation of Whipple's disease. <i>Annals of Internal Medicine</i> , 1984 , 101, 58-9	8	16